|
| Eflornithine hydrochloride hydrate Basic information |
| Eflornithine hydrochloride hydrate Chemical Properties |
Melting point | >210°C (dec.) | storage temp. | Inert atmosphere,2-8°C | solubility | Soluble in Water (up to 25 mg/ml). | form | White powder | color | White | Merck | 14,3522 | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in distilled water may be stored at -20° for up to 3 months. | CAS DataBase Reference | 96020-91-6 |
RTECS | RM2981900 | HS Code | 2922493800 |
| Eflornithine hydrochloride hydrate Usage And Synthesis |
Description | Difluoromethylornithine HCl (96020-91-6) is a selective inhibitor of ornithine decarboxylase.1?Induces apoptosis in a variety of cells.2?Difluoromethylornithine HCl displays cancer chemopreventive activity.3?Cell permeable. Active in vivo. | Chemical Properties | White Solid | Uses | Eflornithine hydrochloride hydrate is irreversible inhibitor of ornithine decarboxylase, an enzyme involved in polyamine biosynthesis. Antineoplastic; antipneumocystic; antiprotozoal (Trypanosoma). Used in the treatment of hirsutism. | Definition | ChEBI: Eflornithine hydrochloride monohydrate is the hydrochloride and hydrate of the trypanocidal drug eflornithine. It is a hydrochloride and a hydrate. It contains an eflornithine. | Brand name | Ornidyl (Sanofi Aventis); Vaniqa (Skinmedica). | General Description | A cell-permeable, anticancer agent that acts as a specific and irreversible inhibitor of ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. Inhibits B16 melanoma-induced angiogenesis in ovo and proliferation of vascular endothelial cells in vitro. | Biochem/physiol Actions | Primary TargetODC | References | 1) Verma et al. (1990), Inhibition of tumor promotion by DL-alpha-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase; Basic Life Sci., 52 195
2) Takahashi et al. (2000), Alpha-difluoromethylornithine induces apoptosis as well as anti-angiogenesis in the inhibition of tumor growth and metastasis in a human gastric cancer model; Int. J. Cancer, 85 243
3) Meyskens et al. (1999), Development of difluoromethylornithine (DFMO) as a chemoprevention agent; Clin. Cancer Res., 5 945 |
| Eflornithine hydrochloride hydrate Preparation Products And Raw materials |
|